{
    "Trade/Device Name(s)": [
        "Creatine Kinase"
    ],
    "Submitter Information": "Roche Diagnostics Operations (RDO)",
    "510(k) Number": "K160570",
    "Predicate Device Reference 510(k) Number(s)": [
        "K951595"
    ],
    "Regulatory Class": "II",
    "Product Code(s)": [
        "JHS"
    ],
    "Summary Letter Date": "February 26, 2016",
    "Summary Letter Received Date": "February 29, 2016",
    "Submission Date": "February 26, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1215"
    ],
    "Regulation Name(s)": [
        "Creatine phosphokinase/creatine kinase or isoenzymes test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatine kinase (CK)",
        "CK isoenzymes"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Li-Heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Serum Gel Separation tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Roche/Hitachi cobas c systems",
        "cobas c 501 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "UV test",
        "Photometric measurement",
        "Enzymatic assay"
    ],
    "Methodologies": [
        "Quantitative determination",
        "Enzyme activation by N-acetylcysteine",
        "Coupled enzymatic reactions",
        "Absorbance measurement at 340 nm and 546 nm"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Roche Creatine Kinase assay for quantitative determination of CK in serum and plasma using photometric enzymatic methods on cobas c analyzers",
    "Indications for Use Summary": "In vitro quantitative test for creatine kinase (CK) in human serum and plasma to aid in diagnosis and monitoring of myocardial infarction and myopathies such as progressive Duchenne muscular dystrophy",
    "fda_folder": "Clinical Chemistry"
}